FDA Brief

Warning letters Drugs

FDA warning letter to

Safari Stem Cell, LLC

High riskIssued Apr 5, 2024Posted May 28, 2024Division of Biological Products Operations II

FDA warned Safari Stem Cell for selling unapproved stem cell animal drugs made without required CGMP controls, including sterility testing.

What happened

FDA inspected Safari from May 1, 2023, through May 4, 2023, and reviewed its website and social media. FDA found Safari markets canine and feline stem cell, platelet-rich plasma, and conditioned media products to treat diseases such as arthritis, kidney disease, and IVDD. The inspection found CGMP (current good manufacturing practice) deviations, and FDA noted that although Safari said it would cease operations, its website still indicated it was manufacturing and distributing stem cell products.

What FDA found

  1. Markets stem cell products as drugs to treat diseases in pets without FDA approval.

    FD&C Act sections 201(g)(1)(B), 201(v), 512(a), and 501(a)(5) [21 U.S.C. ยงยง 321(g)(1)(B), 321(v), 360b(a), 351(a)(5)]
  2. Failed to establish written production and process control procedures for stem cells from umbilical cord and bone marrow.

    21 CFR 211.100(a)
  3. Failed to establish and follow written in-process controls and tests and did not validate manufacturing processes for stem cells from adipose tissue, umbilical cord, and bone marrow.

    21 CFR 211.110(a)
  4. Failed to perform appropriate laboratory testing, including sterility testing, on at least some batches of stem cell products given intravenously or intrathecally.

    21 CFR 211.165(b)
  5. Failed to have an environmental monitoring system in the aseptic processing area where stem cell products are made.

    21 CFR 211.42(c)(10)(iv)
  6. Failed to establish and follow written cleaning procedures and keep cleaning records for manufacturing equipment.

    21 CFR 211.67(b) and 21 CFR 211.67(c)

What FDA wants

FDA asks Safari to notify it in writing within 15 working days of the specific steps taken to address the violations, including explanations and documentation. If corrective actions cannot be completed in that time, Safari must state the reason and the time within which it will do so.

Who should pay attention

  • veterinary clinics that offer or refer stem cell therapies
  • pet owners considering regenerative stem cell treatments
  • companies marketing cell-based animal drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AHC Products, Inc.

    AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.

    High risk
  2. The Fish Aid

    FDA warned The Fish Aid it sells unapproved, unlisted antibiotics for aquarium fish and birds without veterinary oversight.

    High risk
  3. DK Hardware Supply

    FDA warns DK Hardware Supply over unapproved, unlisted aquarium-fish antibiotic drugs.

    High risk
  4. Synergy Animal Products, Inc.

    Synergy Animal Products marketed unapproved animal drugs for dairy cows with inadequate directions and major manufacturing violations.

    High risk